Seeking Alpha

Seeking Alpha Portfolio App for iPad

813 people get ALNY articles and Market Currents by email alert.

Get email alerts on ALNY »

ALNY

Alnylam Pharmaceuticals, Inc.

5/25/2013, 9:01 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 24, 9:28 AM Deutsche Bank starts Alnylam Pharmaceuticals (ALNY) at Buy with a $40 price target representing a 42.5% premium to Thursday's close. Analyst Alethia Young says the company "has the chance to unlock significant long-term value as they commercialize their assets in the clinic during 2017 and beyond, leading to $4B+ in unadjusted sales." Comment! [Healthcare]
Friday, May 17, 9:46 AM Alnylam Pharmaceuticals (ALNY -0.2%) pares the early gains it racked up after saying preclinical data demonstrate RNAi therapeutics targeting ALAS-1 can suppress the "toxic heme biosynthesis intermediaries that cause the symptoms and disease pathology of acute intermittent porphyria." The company says the findings support its ALN-AS1 program. (PR) Comment! [Healthcare]
Monday, May 6, 4:09 PM Alnylam Pharmaceuticals (ALNY): Q1 EPS of -$0.15. Revenue of $18.6M beats by $3.04M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, May 6, 12:10 AM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
Sunday, May 5, 5:35 PM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
Monday, February 11, 11:00 AM Alnylam Pharmaceuticals (ALNY -3.4%) dips after MLV cut the shares to Hold from Buy. The firm says it prefers to take a cautious stance ahead of pending details of disease-modifying data from its lead partnered programs. One such program is its strategic alliance with The Medicines Co. (MDCO -3%) to develop ALN-PCS, an RNAi therapeutic program for the treatment of hypercholesterolemia. Comment! [Healthcare, On the Move]
Thursday, February 7, 4:08 PM Alnylam Pharma (ALNY): Q4 Gaap-EPS of -$1.20 beats by $0.25. Revenue of $8.5M misses by $7.32M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, February 7, 12:10 AM Notable earnings after Thursday’s close: AGNC, ALNY, ASYS, ATHN, ATVI, AVNR, CSTR, DCT, FLT, G, HAS, LNKD, MCHP, NCR, NFG, NUAN, OPEN, PRI, RGC, RSG, RVBD, SNCR, SPWR, TSRA, UBNT, WWWW, XL Comment! [Earnings]
Wednesday, February 6, 5:35 PM Notable earnings after Thursday’s close: AGNC, ALNY, ASYS, ATHN, ATVI, AVNR, CSTR, DCT, FLT, G, HAS, LNKD, MCHP, NCR, NFG, NUAN, OPEN, PRI,RGC, RSG, RVBD, SNCR, SPWR, TSRA, UBNT, WWWW, XL Comment! [Earnings]
Monday, February 4, 12:49 PM The Medicines Company (MDCO -1.5%) says it's formed an exclusive global alliance with Alnylam Pharmaceuticals (ALNY -2.6%) for the development and commercialization of ALNY's ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia. The deal could net ALNY $205M plus double-digit royalties if the collaboration is successful, and an early-stage trial has already showed success. Comment! [Healthcare]
Monday, February 4, 8:22 AM The Medicines Company (MDCO) is licensing the rights to cholesterol-lowering drug ALN-PCS from Alnylam Pharmaceuticals (ALNY), with Medicines paying $25M up front, as much as $180M in milestones, and then royalties. The treatment inhibits a protein called PCSK9 and is seen as an alternative to statins such as Lipitor. However, ALN-PCS is only in Phase I trials. Comment! [Healthcare]
Thursday, January 17, 1:05 PM Alnyam Pharmaceuticals (ALNY -1.3%) slips on further dilution as the underwriters of its recent secondary offering exercise options to purchase an additional 1.2M shares at $20.13. The purchase increases the size of the offering from 8M to 9.2M and boosts the net proceeds to ALNY to $173.8M. Comment! [Healthcare, On the Move]
Monday, January 14, 4:10 PM Alnylam Pharmaceuticals (ALNY) announces a secondary offering of approximately $125M. All of the shares in the offering are to be sold by Alnylam. JPMorgan (JPM) and Morgan Stanley (MS) are acting as joint book-runners. 1 Comment [Healthcare]
Wednesday, December 12, 2012, 2:45 PM Alnylam Pharmaceuticals (ALNY +4%) trades up after Piper Jaffray raised its rating to Neutral and increased its price target from $19 to $25. Piper notes that with the Tekmira litigation behind them, ALNY can now focus more on clinical progress. Specifically, the firm expects the drug developer to have Phase II data on its ALN-TTR02 this summer to prepare for pivotal studies by year-end, adding that ALNY also plans to file applications with the FDA on sub-cutaneous hemophilia therapy formulations of ALN-TTR02 and ALN-AT3. Comment! [Healthcare, On the Move]
Monday, December 10, 2012, 2:08 PM Alnylam Pharmaceuticals (ALNY +5.2%) trades up after reporting encouraging pre-clinical data for its RNAi therapeutic program to treat of hemophilia and other bleeding disorders. The drug candidate produced up to a four-fold increase in thrombin - a protein that plays a role in blood coagulation - in testing with non-human primates. The company says it eventually plans to have five different medications in clinical development by the end of 2015. Comment! [Healthcare, On the Move]
Tuesday, November 13, 2012, 10:31 AM Alnylam Pharmaceuticals (ALNY +4.8%) is higher this morning after reaching a settlement with Tekmira Pharmaceuticals (TKMR +19.3%) resolving all litigation issues between the companies. It also signed a new licensing agreement that restructures the relationship and provides clarity on all intellectual property and licensing issues. As a result, TKMR will receive $65M within 10 days and is eligible to receive an additional $10M in near-term milestone payments in 2013. (Conference Call Webcast Replay) Comment! [Healthcare, On the Move]